Scientific Program and Conference Schedule
Saturday, October 19

Saturday, October 19

3:00 p.m.-4:30 p.m.  Educational Session 1:  
Cancer Genomics  
Veterans Memorial Auditorium  

Co-Chairpersons: Matthew L. Meyerson, Dana-Farber Cancer Institute, Boston, MA, USA, and P. Andrew Futreal, The University of Texas MD Anderson Cancer Center, Houston, TX, USA  

Somatic alterations in human cancer genomes*  
Matthew L. Meyerson  

Challenges and opportunities for genomic medicine  
P. Andrew Futreal  

Advances and future of finding cancer-associated genes  
Gad Getz, Broad Institute of MIT and Harvard, Cambridge, MA, USA, and Massachusetts General Hospital, Boston, MA, USA  

4:30 p.m.-4:45 p.m.  Break  
Boylston Street Hallway

4:45 p.m.-6:15 p.m.  Educational Session 2: PI3K and MEK Pathway Inhibitors  
Veterans Memorial Auditorium  

Co-Chairpersons: Lewis C. Cantley, Weill Cornell Medical College of Cornell University, New York, NY, USA, and Richard M. Marais, Cancer Research UK Manchester Institute, Manchester, United Kingdom  

BRAF and RAS signaling in melanoma: From basic biology to clinical exploitation  
Richard M. Marais  

Title to be announced  
Neal Rosen, Memorial Sloan-Kettering Cancer Center, New York, NY, USA  

Matrix-dependent adaptive resistance to targeted therapy  
Joan S. Brugge, Harvard Medical School, Boston, MA, USA

6:30 p.m.-8:00 p.m.  Networking Reception  
Sheraton Boston Hotel, Grand Ballroom

Sunday, October 20

8:00 a.m.-10:05 a.m.  Opening Plenary Session:  
Opening Remarks and Keynote Lectures  
Veterans Memorial Auditorium

Welcome and Opening Remarks  
Jeffrey A. Engelman, Massachusetts General Hospital, Charlestown, MA, USA  

Lee J. Helman, National Cancer Institute, Bethesda, MD, USA  

Roger Stupp, University Hospital Zurich, Zurich, Switzerland

Keynote Lectures  
Chairperson: Jeffrey A. Engelman, Massachusetts General Hospital, Charlestown, MA, USA

Wnt signaling, Lgr5 stem cells, and cancer*  
Hans Clevers, Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences and University Medical Centre, Utrecht, The Netherlands  

Targeting the PD-1 pathway: Resetting the balance between the immune system and cancer  
Suzanne L. Topalian, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD, USA

10:05 a.m.-10:30 a.m.  Break  
Boylston Street Hallway

*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings.
**10:30 a.m.-12:30 p.m.**  
**Plenary Session 1:**  
**Latest Advances to Overcome Resistance to Targeted Therapies**  
Veterans Memorial Auditorium

**Co-Chairpersons:** René Bernards, Netherlands Cancer Institute, Amsterdam, The Netherlands, and Alice T. Shaw, Massachusetts General Hospital Cancer Center, Boston, MA, USA

Using synthetic lethality to find effective combination therapies for cancer*

René Bernards

Mechanisms of resistance to RAF/MEK inhibitors

David B. Solit, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Overcoming acquired resistance to first-generation kinase inhibitors in lung cancer

William Pao, Vanderbilt University, Nashville, TN, USA

Mechanisms of acquired resistance to ALK/ROS1 inhibitors*

Alice T. Shaw

**12:30 p.m.-3:00 p.m.**  
**Poster Session A**  
(not eligible for CME credit)  
Exhibit Hall C-D

Angiogenesis and Antiangiogenesis Agents 1  
Animal Models 1  
Apoptosis, Necrosis, and Autophagy 1  
Bioinformatics  
Biomarkers 1  
Cancer Stem Cells 1  
Cellular Responses to Therapy 1  
Clinical Trials 1  
Drug Delivery  
Drug Resistance and Modifiers 1  
Drug Screening 1  
EGFR/Hr2 1  
Epigenetic Targets  
Genomics, Proteomics, and Target Discovery 1

12:30 p.m.-3:00 p.m.  
**Exhibit Show**  
Exhibit Hall C-D

**3:15 p.m.-5:15 p.m.**  
**Plenary Session 2: Targeting the Metabolic Basis of Cancer**  
Veterans Memorial Auditorium

**Co-Chairpersons:** Eyal Gottlieb, The Beatson Institute for Cancer Research, Glasgow, United Kingdom, and Craig B. Thompson, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

The metabolic phase of the cell cycle*

Eyal Gottlieb

The genetic basis of kidney cancer: A metabolic disease*

W. Marston Linehan, National Cancer Institute, Bethesda, MD, USA

Ras-induced macropinocytosis: Metabolic adaptation to signaling in the absence of adequate nutrients*

Craig B. Thompson

Targeting IDH mutations in cancer*

Katharine Yen, Agios Pharmaceuticals, Cambridge, MA, USA

*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings.
**Proffered Paper Session 1**

**Chairperson:** Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA

**PR01** Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange**

*Michael Burns,* Vanderbilt University School of Medicine, Nashville, TN, USA

**PR02** LEE011: An orally bioavailable, selective small molecule inhibitor of CDK4/6—Reactivating Rb in cancer**

*Sunkyu Kim,* Novartis Institutes for BioMedical Research, Cambridge, MA, USA

**PR03** Selective sensitization of mutant K-Ras cancer cells to DNA damage-based therapies by targeting wild type H- and N-Ras**

*Elda Grabocka,* NYU Langone Medical Center, New York, NY, USA

**PR04** BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition**

*Katherine Hutchinson,* Vanderbilt University, Nashville, TN, USA

---

**Poster Session A (continued)**

(Not eligible for CME credit)

Exhibit Hall C-D

---

**Exhibit Show (continued)**

Exhibit Hall C-D

---

**AACR Women in Cancer Research (WICR) Career Mentoring Session**

*Organized by the AACR Women in Cancer Research Council* (not eligible for CME credit)

Sheraton Boston Hotel, Fairfax Room

---

**Co-Chairpersons:** Jessie English, Dana-Farber Cancer Institute, Boston, MA, USA; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Victoria Richon, Sanofi Oncology, Cambridge, MA, USA; and Lillian Siu, University Health Network Princess Margaret Hospital, Toronto, ON, Canada

This session has been designed for graduate students, medical students and residents, and clinical and postdoctoral fellows. Although all conference attendees are invited to attend this session, it is geared toward early-career female investigators. Advance registration was encouraged and onsite registration will be available on a first-come, first-served basis. Seating is limited.

Following a keynote address by Kornelia Polyak, M.D., Ph.D., attendees will meet, network, and learn from leading senior scientists in cancer research. Please join us! (A reception with food and drink is included.)

Keynote Address: Dream, Dare, Succeed

*Kornelia Polyak,* Dana-Farber Cancer Institute, Boston, MA, USA

**Featured Mentors:**

Careers in Academia

*James E. Bradner,* Dana-Farber Cancer Institute, Boston, MA, USA

Careers in Industry

*Pamela Carroll,* Janssen, Pharmaceutical Companies of Johnson & Johnson, Cambridge, MA, USA

---

**An extended abstract for this presentation is available in the Proffered Papers section of the Proceedings.**
Writing a CV
Simone Fulda, J.W. Goethe University of Frankfurt, Frankfurt, Germany

Clinical Translational Research Careers for Early-Career Scientists
Judy Garber, Dana-Farber Cancer Institute, Boston, MA, USA

Oral Presentations
Lee J. Helman, National Cancer Institute, Bethesda, MD, USA

Translational Cancer Research for Basic Scientists
W. Marston Linehan, National Cancer Institute, Bethesda, MD, USA

A Career in Drug Discovery
Jeanette M. Wood, AstraZeneca, Macclesfield, Cheshire, United Kingdom

Monday, October 21

8:00 a.m.-10:00 a.m.  Plenary Session 3: Epigenetic Regulators as Therapeutic Targets
Veterans Memorial Auditorium

Co-Chairpersons: James E. Bradner, Dana-Farber Cancer Institute, Boston, MA, USA, and Chas Bountra, University of Oxford, Headington, United Kingdom

Working together to identify new epigenetic targets for cancer*
Chas Bountra

Targeting enhancers in cancers
James E. Bradner

Designing p300/CBP histone acetyltransferase inhibitors for cancer*
Philip A. Cole, Johns Hopkins University School of Medicine, Baltimore, MD, USA

10:00 a.m.-10:30 a.m.  Break
Boylston Street Hallway

10:30 a.m.-12:30 p.m.  Plenary Session 4: Targeting KRAS Mutant Cancers
Veterans Memorial Auditorium

Co-Chairpersons: Julian Downward, Cancer Research UK, London, United Kingdom, and Kevan M. Shokat, University of California, San Francisco, CA, USA

Developing therapies for Ras-driven cancers*
Karen Cichowski, Brigham and Women’s Hospital, Boston, MA, USA

Targeting MEK in KRAS mutant lung cancer*
Pasi A. Jänne, Dana-Farber Cancer Institute, Boston, MA, USA

Direct targeting of mutant Ras proteins
Kevan M. Shokat

Synthetic lethal approaches to targeting Ras mutant cancers*
Julian Downward

*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings.
Scientific Program and Conference Schedule
Monday, October 21

12:30 p.m.-3:00 p.m.  Poster Session B
(not eligible for CME credit)
Exhibit Hall C-D

Angiogenesis and Antiangiogenesis Agents 2
Animal Models 2
Apoptosis, Necrosis, and Autophagy 2
Biomarkers 2
Cancer Stem Cells 2
Cell Cycle Regulators
Cellular Responses to Therapy 2
Clinical Trials 2
DNA Repair and Modulation 1
Drug Design
Drug Resistance and Modifiers 2
EGFR/Her2 2
Gene Therapies
Genomics, Proteomics, and Target Discovery 2
Imaging
Metabolism 1
Metastasis and Invasion 2
Molecular Classification of Tumors
mTOR/PI3-Kinase 2
New Molecular Targets 2
Other
Pharmacokinetics and Pharmacodynamics 2
RNA and RNA-Based Technologies and Therapies
Target Identification and Validation 2
Therapeutic Agents: Biological 2
Therapeutic Agents: Other 2
Therapeutic Agents: Small Molecule Kinase Inhibitors 2
Tumor Immunology Targets

3:15 p.m.-5:15 p.m.  Concurrent Session 1: RNAi Therapeutics: Hype or Hope?
Ballroom B

Co-Chairpersons: Frank McCormick, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA, and Judy Lieberman, Harvard Medical School, Boston, MA, USA

Opportunities for systemic treatment using siRNA in nanoparticles
Frank McCormick
Targeting basel-like TNBCs and epithelial tumor-initiating cells with aptamer-siRNA chimeras*
Judy Lieberman
Prospects for miRNA- and IncRNA-based cancer therapeutics*
Reuven Agami, Netherlands Cancer Institute, Amsterdam, The Netherlands
RNAi therapeutics in cancer: Clinical results with nanoparticle siRNA delivery systems
Jared Gollob, Alnylam Pharmaceuticals, Inc., Cambridge, MA, USA

3:15 p.m.-5:15 p.m.  Concurrent Session 2: Molecular Diagnostics: Bringing the Latest Technologies to Clinical Development
Ballroom A

Co-Chairpersons: Jean-Charles Soria, Institute Gustave-Roussy, Villejuif, France, and Anthony John Iafrate, Massachusetts General Hospital, Boston, MA, USA

CTCs in small cell lung cancer: Biomarkers and biology*
Caroline Dive, Cancer Research UK Manchester Institute, Manchester, United Kingdom

From precision medicine to personalized medicine in metastatic breast cancer patients*
Fabrice André, Institut Gustave-Roussy, Villejuif, France

12:30 p.m.-3:00 p.m.  Exhibit Show
Exhibit Hall C-D

*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings.
Targeted multiplexed DNA sequencing for biomarker discovery and clinical diagnosis*

Michael F. Berger, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Title to be announced

Anthony John Iafrate

3:15 p.m.-5:15 p.m.  Concurrent Session 3: Novel Laboratory Models to Assess Cancer Therapeutics
Veterans Memorial Auditorium

Co-Chairpersons: William R. Sellers, Novartis Institutes for BioMedical Research, Cambridge, MA, USA, and Norman E. Sharpless, The Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA

Drug testing in genetically engineered murine models*  
Norman E. Sharpless

Conditionally reprogrammed cells for personalized medicine*  
Richard Schlegel, Georgetown University School of Medicine, Washington, DC, USA

Use of the zebrafish for studying cancer genetics*  
Leonard I. Zon, HHMI/Boston Children’s Hospital, Boston, MA, USA

Towards robust and systematic translational systems for cancer therapeutic development  
William R. Sellers

3:15 p.m.-5:15 p.m.  Concurrent Session 4: Targeting Apoptotic Regulators
Ballroom C

Co-Chairpersons: Anthony G. Letai, Dana-Farber Cancer Institute, Boston, MA, USA, and Simone Fulda, J. W. Goethe University of Frankfurt, Frankfurt, Germany

Poking cancer cells with BH3 profiling to personalize cancer therapy*  
Anthony G. Letai

Discovery of Mcl-1 inhibitors using fragment-based methods*  
Stephen W. Fesik, Vanderbilt University School of Medicine, Nashville, TN, USA

Modeling Myc as a therapeutic cancer target  
Gerard I. Evan, University of Cambridge, Cambridge, United Kingdom

Targeting death receptors and SMAC mimetics*  
Simone Fulda

5:30 p.m.-6:30 p.m.  Proffered Paper Session 2
Veterans Memorial Auditorium

Chairperson: Roger Stupp, University Hospital Zurich, Zurich, Switzerland

PR05 Resistance to Hedgehog inhibitor through Smoothened receptor mutation in basal cell carcinoma**  
Sabrina Pricl, University of Trieste, Trieste, Italy

PR06 A functional screen of the epigenome identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers**  
Zainab Jagani, Novartis Institutes for BioMedical Research, Cambridge, MA, USA

PR07 Novel oncogenic mutations in the beta subunit of heteromeric G-proteins identified by functional cDNA library screening*  
Akinori Yoda, Dana-Farber Cancer Institute, Boston, MA, USA

PR08 Loss of oncogenic Notch1 signaling contributes to PI3 kinase inhibitor resistance in T lineage leukemia**  
Monique Dail, University of California, San Francisco, CA, USA

6:30 p.m.-7:30 p.m.  Poster Session B (continued)
(not eligible for CME credit)
Exhibit Hall C-D

*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings.
**An extended abstract for this presentation is available in the Proffered Papers section of the Proceedings.
Scientific Program and Conference Schedule
Monday, October 21

6:30 p.m.-7:30 p.m.  
**Exhibit Show (continued)**
Exhibit Hall C-D

7:30 p.m.-9:00 p.m.  
**AACR Chemistry in Cancer Research (CICR) Working Group Town Hall**
(not eligible for CME credit)
Sheraton Boston Hotel, Commonwealth Room

**Chairperson: Michael J. Luzzio**, Novartis Institutes for BioMedical Research, Cambridge, MA, USA

The Chemistry in Cancer Research (CICR) Working Group brings together cancer-focused scientists in chemistry and chemistry-related fields to discuss the present status and future promise of chemistry in the advancement of the prevention and cure of cancer. All CICR members are encouraged to attend and all interested Conference registrants are also invited. This event will provide an opportunity to meet with Dr. Michael J. Luzzio, CICR Steering Committee Chair, raise questions, and contribute ideas to help shape future CICR initiatives. Attendees can also learn about membership in CICR, meet the members of the Steering Committee, and connect with colleagues. A networking reception will follow.

**Tuesday, October 22**

8:00 a.m.-10:00 a.m.  
**Plenary Session 5: Genomic Heterogeneity in Cancers: Implications for Responsiveness**
Veterans Memorial Auditorium

**Co-Chairpersons: Elaine R. Mardis**, Washington University School of Medicine, Saint Louis, MO, USA, and **Kornelia Polyak**, Dana-Farber Cancer Institute, Boston, MA, USA

Heterogeneity in DCIS and invasive breast cancers*

**Kornelia Polyak**

Mathematical modeling of tumor heterogeneity
**Franziska Michor**, Dana-Farber Cancer Institute, Boston, MA, USA

Phylogenetic quantification of intratumor heterogeneity predicts time to relapse in high-grade serous ovarian cancer*
**Florian Markowitz**, Cancer Research UK Cambridge Institute, Cambridge, United Kingdom

Temporal evaluation of cancer heterogeneity*
**Elaine R. Mardis**

10:00 a.m.-10:30 a.m.  
**Break**
Boylston Street Hallway

10:30 a.m.-12:30 p.m.  
**Plenary Session 6: CTCs: Noninvasive Monitoring of Cancers**
Veterans Memorial Auditorium

**Co-Chairpersons: Daniel A. Haber**, Massachusetts General Hospital, Charlestown, MA, USA, and **Alberto Bardelli**, IRCC - University of Turin, Medical School, Candiolo, Italy

Liquid biopsies to monitor response and resistance to targeted therapies*
**Alberto Bardelli**

Cancer exomes in plasma to track clonal evolution and resistance
**Carlos M. Caldas**, Cancer Research UK Cambridge Research Institute, Cambridge, United Kingdom

Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing*
**Mark Sausen**, Personal Genome Diagnostics, Baltimore, MD, USA

Molecular characterization of circulating tumor cells*
**Daniel A. Haber**

*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings.
12:30 p.m.-3:00 p.m.  
**Poster Session C**  
(not eligible for CME credit)  
Exhibit Hall C-D

Angiogenesis and Antiangiogenesis Agents 3  
Animal Models 3  
Apoptosis, Necrosis, and Autophagy 3  
Biomarkers 3  
Cellular Responses to Therapy 3  
Chemistry  
Chemoprevention  
Clinical Trials 3  
DNA Repair and Modulation 2  
Drug Metabolism, Transport, and Biodistribution  
Drug Resistance and Modifiers 3  
Drug Screening 2  
EGFR/Her2 3  
Genomics, Proteomics, and Target Discovery 3  
Heat Shock Proteins  
Hormonal Agents and Therapy  
MAPK Pathways  
Metabolism 2  
Monoclonal Antibodies  
mTOR/Pi3-Kinase 3  
New Molecular Targets 3  
Novel Assay Technology 2  
Pediatric-Early Drug Development  
Protein-Protein Interaction  
Radiotherapeutics  
Target Identification and Validation 3  
Therapeutic Agents: Biological 3  
Therapeutic Agents: Other 3  
Therapeutic Agents: Small Molecule Kinase Inhibitors 3  
Topoisomerase Inhibitors  
Toxicology  
Tumor Microenvironment  
Tumor Suppressors  

3:15 p.m.-5:15 p.m.  
**Concurrent Session 5: Back to the Future: Targeting Cell Cycle and DNA Repair**  
Ballroom C

**Co-Chairpersons:** Alan D. D’Andrea, Dana-Farber Cancer Institute, Boston, MA, USA, and Yves G. Pommier, National Cancer Institute, Bethesda, MD, USA  
PARP inhibitors: Trapping of PARP and rationale for combinations*  
Yves G. Pommier  
Targeting the Fanconi anemia/BRCA pathway*  
Alan D. D’Andrea  
Targeting oncogene-induced DNA damage for cancer therapy*  
Oscar Fernandez-Capetillo, Spanish National Cancer Research Centre (CNIO), Madrid, Spain  
Novel DNA repair targets for anticancer treatments*  
Thomas Helleday, Karolinska Institute, Stockholm, Sweden

3:15 p.m.-5:15 p.m.  
**Concurrent Session 6: EMT, Cellular Plasticity, Cellular Differentiation, and Response to Therapies**  
Ballroom B

**Co-Chairpersons:** Jeffrey E. Settleman, Genentech, Inc., South San Francisco, CA, USA, and Robert A. Weinberg, MIT Whitehead Institute for Biomedical Research, Cambridge, MA, USA  
Cancer stem cells and the EMT*  
Robert A. Weinberg  
Breast cancer stem cells*  
Jenny C. Chang, Methodist Cancer Center, The Methodist Hospital, Houston, TX, USA  
Cell plasticity promotes drug resistance and pathway redundancy*  
John D. Haley, Network Pharmacology LLC, Sea Cliff, NY, USA  
Reversible tolerance to anticancer drugs*  
Jeffrey E. Settleman

---

*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings.  
**An extended abstract for this presentation is available in the Proffered Papers section of the Proceedings.
3:15 p.m.-5:15 p.m. Concurrent Session 7: Developing Combination Therapy Approaches in the Lab and Clinic Veterans Memorial Auditorium

Co-Chairpersons: José Baselga, Memorial Sloan-Kettering Cancer Center, New York, NY, USA, and Jeffrey A. Engelman, Massachusetts General Hospital, Charlestown, MA, USA

Monitoring downstream responses to MAP kinase pathway inhibitor therapy in BRAF mutant melanoma to support rational combinations strategies*  
Keith Thomas Flaherty, Massachusetts General Hospital Cancer Center, Boston, MA, USA

Novel combinations for KRAS and PIK3CA mutant cancers  
Jeffrey A. Engelman  
Rationale for combined PI3K and mTOR blockade  
José Baselga

Title to be announced  
James A. Fagin, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

5:30 p.m.-6:30 p.m. Proffered Paper Session 3 Veterans Memorial Auditorium

Chairperson: Lee J. Helman, National Cancer Institute, Bethesda, MD, USA

PR09 Synergistic activity of CRLX101, a nanopharmaceutical in phase II clinical trials, with antiangiogenic therapies mediated through HIF-1alpha inhibition: A translational research program**  
Scott Eliasof, Cerulean Pharma Inc., Cambridge, MA, USA

PR10 Is CNS availability for oncology a no-brainer? Discovery of PF-06463922, a novel small molecule inhibitor of ALK/ROS1 with preclinical brain availability and broad spectrum potency against ALK-resistant mutations**  
Ted W. Johnson, Pfizer, Inc., San Diego, CA, USA

PR11 Use of a DNA damage multiplex immunofluorescence assay to monitor pharmacodynamic markers following in vitro exposure to therapeutic agents**  
Allison M. Marrero, SAIC-Frederick, Frederick National Laboratory for Cancer Research, Frederick, MD, USA

3:15 p.m.-5:15 p.m. Concurrent Session 8: Using Genomics From Cell Line Screens to Inform Drug Development Ballroom A

Co-Chairpersons: Mathew Garnett, Wellcome Trust Sanger Institute, Cambridge, United Kingdom, and Levi A. Garraway, Dana-Farber Cancer Institute, Boston, MA, USA

Title to be announced  
Levi A. Garraway

Therapeutic biomarker discovery in cancer cells*  
Mathew Garnett

Synthetic lethal screens using RNAi*  
Christopher Lord, Institute of Cancer Research, London, United Kingdom

6:30 p.m.-7:30 p.m. Poster Session C (continued) (not eligible for CME credit) Exhibit Hall C-D

6:30 p.m.-7:30 p.m. Exhibit Show (continued) Exhibit Hall C-D

*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings.
**An extended abstract for this presentation is available in the Proffered Papers section of the Proceedings.
Wednesday, October 23

8:00 a.m.-10:00 a.m.  Plenary Session 7: Immunotherapy
Veterans Memorial Auditorium

Co-Chairpersons: Alexander M. Marie Eggermont, Institute Gustave-Roussy and University Paris-Sud, Paris, France, and Carl H. June, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA

Immune checkpoint blockade in cancer therapy: New insights and opportunities*
James P. Allison, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

The renaissance of immunotherapy*
Alexander M. Marie Eggermont

Mechanisms of protective tumor immunity*
Glenn Dranoff, Dana-Farber Cancer Institute, Boston, MA, USA

Engineered T cell transfer for cancer immunotherapy in the era of synthetic biology: Challenges and opportunities*
Carl H. June

*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings.

10:00 a.m.-10:30 a.m.  Break
Boylston Street Hallway

10:30 a.m.-12:30 p.m.  Plenary Session 8: Combining Immunotherapies, Immune Modulators, and Targeted Therapies: Regulatory Opportunities and Challenges
Veterans Memorial Auditorium

Moderator: F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA, USA

Introductions
F. Stephen Hodi

Title to be announced
Ke Liu, U.S. Food and Drug Administration-CBER, Rockville, MD, USA

Title to be announced
Michael A. Postow, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Title to be announced
Renzo Canetta, Bristol-Myers Squibb Co., Wallingford, CT, USA

Title to be announced
Louise M. Perkins, Melanoma Research Foundation, Washington, DC, USA

Panel Discussion/Q & A with audience

12:30 p.m.-12:45 p.m.  Closing Remarks
Veterans Memorial Auditorium

*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings.